Compare PMT & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PMT | PCRX |
|---|---|---|
| Founded | 2009 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | 2009 | 2011 |
| Metric | PMT | PCRX |
|---|---|---|
| Price | $13.13 | $26.32 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | $14.13 | ★ $32.86 |
| AVG Volume (30 Days) | ★ 1.1M | 916.7K |
| Earning Date | 01-29-2026 | 11-06-2025 |
| Dividend Yield | ★ 12.14% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.92 | 0.47 |
| Revenue | $564,655,000.00 | ★ $716,791,000.00 |
| Revenue This Year | N/A | $6.24 |
| Revenue Next Year | $29.66 | $9.53 |
| P/E Ratio | ★ $14.37 | $55.91 |
| Revenue Growth | N/A | ★ 3.14 |
| 52 Week Low | $11.60 | $18.17 |
| 52 Week High | $14.93 | $27.64 |
| Indicator | PMT | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 63.94 | 64.48 |
| Support Level | $12.49 | $25.48 |
| Resistance Level | $12.71 | $27.16 |
| Average True Range (ATR) | 0.21 | 1.00 |
| MACD | 0.03 | 0.15 |
| Stochastic Oscillator | 79.19 | 77.18 |
PennyMac Mortgage Investment Trust is a specialty finance company that invests primarily in residential mortgage loans and mortgage-related assets. The company's operations include activities such as the production and servicing of financial securities based on residential loans and the pooling and reselling of high-credit-quality mortgages. The company operates through three segments: correspondent production, credit-sensitive strategies, interest-rate-sensitive strategies. The Credit sensitive strategies segment generates income via investments in CRT arrangements, subordinate MBS, distressed loans, and real estate.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.